Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary mediastinal large cell lymphoma

J Rodriguez1, W C Pugh, J E Romaguera

  • 1University of Texas M. D. Anderson Cancer Center, Department of Hematology, Houston 77030.

Hematological Oncology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curability Potential of Low-Grade Follicular Lymphoma.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Primary mediastinal large cell lymphoma (PMLCL) is a distinct entity affecting young women, often presenting with mediastinal compression. Its unique immunophenotype and variable treatment outcomes require further investigation for optimal management.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Primary mediastinal large cell lymphoma (PMLCL) is a distinct clinico-pathological entity.
  • Its unique immunophenotype and clinical behavior have generated significant interest.
  • Conflicting reports on treatment response necessitate a literature review.

Purpose of the Study:

  • To review the current literature on the pathological and clinical aspects of PMLCL.
  • To consolidate information on its presentation, characteristics, and outcomes.

Main Methods:

  • A comprehensive review of existing literature was conducted.
  • Data on clinical presentation, pathological profile, and clinical outcome were analyzed.

Main Results:

Related Experiment Videos

  • PMLCL predominantly affects young females and presents with mediastinal compression symptoms.
  • The malignant cells exhibit a CD19+/CD21- immunophenotype, with possible c-myc alterations and absent HLA class 1 expression.
  • Treatment response and outcomes are variable, potentially due to small patient numbers and diverse therapies.

Conclusions:

  • PMLCL is a distinct entity with a female predominance, unique immunophenotype (CD19+/CD21-), and absent HLA class 1 expression.
  • Relapse patterns can resemble Burkitt's lymphoma.
  • Optimal treatment, including radiotherapy, remains to be determined.